VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

V-LSN
Vaccine Information
  • Vaccine Ontology ID: VO_0004079
  • Type: Vaccina virus
  • Preparation: The sequence is derived from the Josiah strain of Lassa virus, isolated from a patient in Sierra Leone (Fisher-Hoch et al., 2000).
  • Virulence:
  • Description: V-LSN is a vaccinia viruses expressing the S-segment Lassa nucleoprotein (Fisher-Hoch et al., 2000).
Host Response

Monkey Response

  • Host Strain: Rhesus and Cynomolgus
  • Vaccination Protocol: All animals received a single vaccination consisting of 0.2 ml of vaccine given intradermally and simultaneously at four separate sites (each forearm and the lateral aspect of each thigh) at a dilution which delivered to each animal a total dose of 10^9 PFU. All animals were challenged subcutaneously with 10^3 to 10^4 PFU of the Josiah strain of Lassa virus in 0.5 ml of phosphate-buffered saline within 36 to 700 days (Fisher-Hoch et al., 2000).
  • Persistence: The latest day on which virus could be recovered from serum was day 14, and that from tissues was day 21. Evidence for persistence elsewhere in tissues or fluids in survivors could not be found by cocultivation of tissues taken up to 112 days following challenge. However, autopsy and biopsy material examined by RT-PCR revealed that viral RNA could be detected at least 112 days after challenge (Fisher-Hoch et al., 2000).
  • Side Effects: Monkeys had marked lymphopenia and higher mean aspartate aminotransferase values than unvaccinated animals. The V-LSN-vaccinated animals were observed to be sicker and died earlier than unvaccinated animals (Fisher-Hoch et al., 2000).
  • Efficacy: Vaccination using the nucleoprotein may protect primates against a lower challenge dose of Lassa virus, however, the V-LSN vaccine was not significantly protective (Fisher-Hoch et al., 2000).
  • Description: 8 of the 11 vaccinated animals died, which shows that this vaccine was not significantly protective. The V-LSN animals appeared to have a shorter and more acute process than unprotected animals. The median day of death for V-LSN animals was day 11.5, compared with day 13 for the control animals. This phenomenon was related to the challenge dose. Back titration of the challenge inoculum used in the final experiment showed that the titer had dropped from 10^4 to 10^3 PFU/ml. The three V-LSN-vaccinated animals in that experiment that received the lower challenge titer survived. These three animals were rhesus monkeys (Fisher-Hoch et al., 2000).
References
Fisher-Hoch et al., 2000: Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. Journal of virology. 2000 Aug; 74(15); 6777-83. [PubMed: 10888616].